Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN

Eledon Pharmaceuticals — Technical Presentation

18 slides from Eledon Pharmaceuticals's technical presentation

  1. Slide 1: Patient-reported outcomes in the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus

    Patient-reported outcomes in the Phase 2 BESTOW trial comparing tegoprubart to tacrolimus in kidney transplant recipients Andrew Adams Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA

  2. Slide 2: BESTOW: a prospective, multicenter, active-controlled, randomized, open-label Phase 2 trial

    BESTOW: a prospective, multicenter, active-controlled, randomized, open-label Phase 2 trial • BESTOW (NCT05983770) was a head-to-head comparison of tacrolimus (calcineurin inhibitor) and tegoprubart (anti-CD40L antibody) in de novo kidney transplant recipients • Alongside safety and efficacy outcome

  3. Slide 3: BESTOW: Safety and efficacy findings

    BESTOW: Safety and efficacy findings • Tegoprubart preserved kidney function eGFR was higher with tegoprubart than tacrolimus BESTOW BESTOW EXTENSION across all measurable time points, including amongst 90 Mean (±SEM) eGFR (mL/min/1.73 m2) * * * patients with rejection who continued treatment 80 70

  4. Slide 4: BESTOW: Safety and efficacy findings

    BESTOW: Safety and efficacy findings BESTOW BESTOW EXTENSION • Tegoprubart preserved kidney function eGFR was higher with tegoprubart than tacrolimus across all measurable time points, including amongst patients with rejection who continued treatment • Tegoprubart adequately controlled rejection BPA

  5. Slide 5: BESTOW: Safety and efficacy findings

    BESTOW: Safety and efficacy findings Most frequently occurring TEAEs (≥ 10% by PT) Cytomegalovirus viremia Leukopenia • Tegoprubart preserved kidney function Anemia Diarrhea eGFR was higher with tegoprubart than tacrolimus Constipation Hypophosphatemia across all measurable time points, including am

  6. Slide 6: BESTOW: Health-Related Quality of Life (HRQoL)

    BESTOW: Health-Related Quality of Life (HRQoL) • Kidney transplantation impacts patient HRQoL1 Study Aim Treatment burden Symptoms that impact physical functioning Clinical outcomes Ongoing psychological distress, with emotional and social impact improved with tegoprubart treatment • PROs Useful for

  7. Slide 7: Tegoprubart showed early improvement in patient-reported HRQoL sustained at Month 12 (1 of 3)

    Tegoprubart showed early improvement in patient-reported HRQoL that was sustained at Month 12 (1 of 3) Burden of kidney disease Effects of kidney disease • KDQOL-SF: timelinea scale on daily life scale HRQoL improvements were 100 100 observed across all 5 subscales 80 90 with tegoprubart, and 4 of 5

  8. Slide 8: Tegoprubart showed early improvement in patient-reported HRQoL sustained at Month 12 (2 of 3)

    Tegoprubart showed early improvement in patient-reported HRQoL that was sustained at Month 12 (2 of 3) Symptoms and problems SF-12 physical component • KDQOL-SF: timelinea scale summary 60 HRQoL improvements were 100 observed across all 5 subscales Mean (±SEM) at Month 12 with tegoprubart, and 4 of

  9. Slide 9: Tegoprubart showed early improvement in patient-reported HRQoL sustained at Month 12 (3 of 3)

    Tegoprubart showed early improvement in patient-reported HRQoL that was sustained at Month 12 (3 of 3) SF-12 mental component summary • KDQOL-SF: timelinea 60 HRQoL improvements were observed across all 5 subscales 55 with tegoprubart, and 4 of 5 subscales with tacrolimus Score 50 HRQoL improved by

  10. Slide 10: Tegoprubart showed greater improvement in key HRQoL measures at Month 12

    Tegoprubart showed greater improvement in key HRQoL measures at Month 12 • KDQOL-SF: change from baselinea Symptoms and problems: greater improvement with tegoprubart vs tacrolimus (9.0 vs 3.3; p < 0.05) SF-12 mental component summary: improved with tegoprubart (+1.5) but declined with tacrolimus (−

  11. Slide 11: Symptom occurrence decreased over time with tegoprubart

    Symptom occurrence decreased over time with tegoprubart MTSOSD-59R Total MTSOSD-59R Scores represent symptom occurrence Tacrolimus: total symptom occurrence initially decreased (higher scores reflect greater symptom occurrence) through Month 6, but then rebounded to baseline levels by Month 12 50 Me

  12. Slide 12: MTSOSD-59R: Symptoms getting better (1 of 3)

    MTSOSD-59R: Symptoms getting better (1 of 3) Participants with occurence (%) Neurological Difference in occurence (%) For symptoms with the greatest between-group difference in altered voice improvement, greater concentration/memory problems improvements (i.e. decreased symptom occurrence) were ting

  13. Slide 13: MTSOSD-59R: Symptoms getting better (2 of 3)

    MTSOSD-59R: Symptoms getting better (2 of 3) Gastrointestinal/metabolic For symptoms with the greatest between-group difference in tiredness improvement, greater increased thirst improvements (i.e. decreased stomach complain/nausea/vomiting symptom occurrence) were lack of energy observed with tegop

  14. Slide 14: MTSOSD-59R: Symptoms getting better (3 of 3)

    MTSOSD-59R: Symptoms getting better (3 of 3) Physical For symptoms with the greatest between-group difference in muscle cramp improvement, greater brittle fingernails improvements (i.e. decreased brittle skin symptom occurrence) were observed with tegoprubart than joint pain tacrolimus for: increase

  15. Slide 15: MTSOSD-59R: Symptoms getting worse (1 of 3)

    MTSOSD-59R: Symptoms getting worse (1 of 3) Neurological For symptoms with the greatest between-group difference in trembling hands worsening, more symptoms got tingling/numbness in hands/feet worse (i.e. increased symptom hearing loss occurrence) with tacrolimus dizziness than tegoprubart for: nigh

  16. Slide 16: MTSOSD-59R: Symptoms getting worse (2 of 3)

    MTSOSD-59R: Symptoms getting worse (2 of 3) Gastrointestinal/metabolic For symptoms with the greatest between-group difference in stomach complain/nausea/vomiting worsening, more symptoms got increased thirst worse (i.e. increased symptom poor appetite occurrence) with tacrolimus diarrhea than tegop

  17. Slide 17: MTSOSD-59R: Symptoms getting worse (3 of 3)

    MTSOSD-59R: Symptoms getting worse (3 of 3) Participants with occurence (%) Physical Difference in occurence (%) For symptoms with the greatest between-group difference in palpitation worsening, more symptoms got menstrual problems worse (i.e. increased symptom occurrence) with tacrolimus warmth of

  18. Slide 18: Conclusions

    Conclusions • Kidney Disease Quality of Life Short Form (KDQOL-SF) • Improvements from baseline to Month 12 were observed in all 5 KDQOL-SF subscales with tegoprubart and in 4 of 5 subscales with tacrolimus • Improvement with tegoprubart on the symptoms and problems scale was both clinically and sta

Eledon Pharmaceuticals — Technical Presentation on 6ix